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Abstract 
The term Richter Syndrome (RS) indicates the transformation of chronic lymphocytic 
leukemia (CLL) into an aggressive lymphoma. RS is a rare complication with an 
aggressive clinical course, bearing an unfavorable prognosis.  
In the majority of cases CLL transforms into RS as diffuse large B cell lymphoma (DLBCL), 
and a clonal relation between the two processes can be found. However, clonally 
unrelated RS can occur and transformations to other histologies beside DLBCL have been 
described. 
Recent data have shed some light on genetic characteristics that can influence and drive 
the transformation from CLL to RS. This molecular information has not been translated yet 
into significant treatment advances, and currently the therapy regimens for RS continue to 
rely on intensive chemotherapy combinations followed by stem cell transplant in suitable 
candidates.  
Based on the rapid pace of discoveries in the field of hematological malignancies and on 
the recent revolution in the therapeutic landscape for CLL and B cell lymphomas, new 
therapeutic options for RS might be available in the upcoming years. 
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Introduction 
In chronic lymphocytic leukemia (CLL), Richter syndrome (RS) is a rare complication. 
However, it has relevant clinical implications due to its aggressive clinical course and poor 
prognosis.  
The specific pathologic features of RS were initially described in 1928 by Maurice Richter 
[1], and approximately 40 years later the term RS was first used referring to a series of 
patients with CLL who developed diffuse large B cell lymphoma (DLBCL) [2]. Currently, 
according to the 2008 World Health Classification of lymphoid neoplasms, RS is defined 
as the transformation of CLL into an aggressive lymphoma [3]. The vast majority of RS 
cases are “classical” transformation to DLBCL and, based on the immunoistochemical 
Has-Choi algorithm [4], they can mainly be categorized as the more aggressive activated 
B-cell subtype (ABC) [5,6]. However, a much less common evolution to Hodgkin 
lymphoma (Hodgkin variant of RS, HVRS) has been described [7]. 
A reliable appraisal of the incidence of RS is difficult to obtain due to the heterogeneity of 
the population studied in the published retrospective analysis, and to the lack of a uniform 
diagnostic approach among centers. It is conceivable that the proportion of patients 
developing RS is generally underestimated because many patients with aggressive clinical 
features will not undergo biopsy. Large retrospective studies including more than 500 
patients with CLL describe a prevalence of RS ranging from 2 to 9% [8-11], with an 
approximate incidence rate of 0.5% per year [11]. In these same studies, the reported 
median time to development of RS is approximately 2 years [10,11], not supporting the 
common notion that RS tend to occur late in the natural history of CLL. A longer interval 
between the diagnosis of CLL and the transformation to RS (median 4.3 years) has been 
reported in a retrospective analysis of patients with HVRS [12]. 
 
Molecular features of RS 
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One of the key molecular characteristic of RS is that this disease includes two distinct 
categories based on its cell of origin: in 80-90% of cases RS is related to the original CLL 
clone (clonally related RS), whereas in a small percentage of RS cases the aggressive 
malignant clone is independent from the original CLL clone (clonally unrelated RS) [6]. 
While the absence of clonal relationship is easily recognized at the time of 
immunophenotypic studies in patients with different immunoglobulin light chain restriction 
between the CLL and DLBCL tissue samples, in cases where the light chain restriction is 
the same additional molecular approaches should be performed to better characterize the 
process. The most widely used method consists in the study of the immunoglobulin heavy 
chain variable region (IGHV) rearrangement through polymerase chain reaction (PCR) and 
sequencing [13]. An identical nucleotide sequence in the IGHV rearrangement between 
CLL and RS samples supports the clonal relationship. However, it needs to be highlighted 
that this analysis is not feasible in all laboratories. Moreover, the study cannot be 
performed in certain patients because of the unavailability of baseline IGHV sequencing of 
the CLL B cells, or because of the presence of a mixed population of CLL and aggressive 
lymphoma in the RS histological sample.  
The distinction between clonally related and unrelated RS has clinical implications. In fact, 
the former, which can be considered a true transformation, has a poor outcome, whereas 
the latter has a significant better prognosis and behaves more like de novo DLBCL [5]. In 
HVRS, the malignant cells morphologically and immunophenotypically resemble classical 
Hodgkin lymphoma Reed–Sternberg cells in the majority of cases. The clonal relation of 
the Reed–Sternberg cell with the original CLL clone has been shown only in some cases, 
but no definitive molecular data on the pathogenesis are available, possibly due to the 
rarity of this variant [12]. 
Recently published molecular data contributed to the understanding of the pathways and 
mechanisms involved in RS transformation. Rossi and colleagues analyzed samples from 
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86 cases of classic RS and found TP53 disruption in 47% and c-MYC abnormalities in 
26%, whereas other genetic alterations that are common in de novo DLBCL were virtually 
absent [5].  
The genetic dissimilarity of RS as compared to DLBCL had already been postulated by 
Fabbri et al., who compared the frequency of the most prevalent genetic lesions in 27 RS 
cases and in 71 newly diagnosed and previously untreated DLBCL cases (ABC n=40; 
Germinal center B-cell, GCB n=31). In their work these authors showed that the genetic 
lesions found in RS significantly differ from that of both de novo ABC DLBCL and GCB 
DLBCL [14]. Chigrinova and colleagues performed a genome-wide DNA profiling analysis 
in CLL (n=315), CLL samples of patients that subsequently developed RS (n=28), de novo 
DLBCL (n=127), and RS (n=59), and compared the specific copy number changes in 
different groups, concluding that the genomic complexity of RS can be considered 
intermediate between CLL and DLBCL [15]. Interestingly, significant differences between 
RS and de novo DLBCL were also detected in terms of methylation profile, underscoring 
that these two entities with similar histopathology are in fact distinct, not only genetically, 
but also epigenetically [16]. 
Chigrinova et al. also described two different pathways of molecular transformation from 
CLL to RS, which are mutually exclusive. In approximately one half of the cases, TP53 and 
CDKN2A aberrations were detected and considered responsible for the RS transformation, 
whereas in one third of patients the presence of trisomy 12, associated with NOTCH1 
mutations, was considered to be implicated in the histologic shift [15]. 
The sequence of molecular progression from indolent to aggressive disease was explored 
by Fabbri and colleagues, who analyzed samples from 9 CLL-RS pairs and from an 
extended panel of 43 RS cases by combining whole-exome sequencing and copy-number 
analysis. The authors showed that usually RS derives from the acquisition by the original 
CLL clone, in a linear fashion, of approximately 20 new genetic lesions, which are 
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nevertheless very heterogeneous [14]. It has also been suggested that in clonally related 
RS - as it happens in progressive CLL- small subclones mutated for TP53 or with other 
detrimental genetic aberrations can be already present in the original CLL clone and later 
expand and become the predominant clone due to the selective pressure of treatment [17].  
The genetic instability driven by the loss of tumor suppressors (TP53 and CDKN2A) and 
by the lack of control of the cell cycle (c-MYC aberrations) may explain the accumulation of 
genetic lesions and the transformation from CLL to RS.  
It has also been proposed that a contributor to the clonal evolution from CLL to RS – in 
particular to HVRS - may be an infection from Epstein-Barr virus (EBV) in patients 
characterized by an extremely dysregulated immune system [7,18].    
 
Clinical risk factors 
The risk of transformation to RS has been associated with few clinical risk factors, such as 
the volume of lymph nodes and advanced Rai or Binet stage at diagnosis [11,13].  
The relationship between treatment and development of RS is controversial. A role of CLL-
directed treatment and in particular the use of specific drugs, in the development of RS 
has been hypothesized. However, patients with CLL receive different type of therapy 
regimens in a sequential manner, and therefore the specific contribution of a single class 
of drugs is difficult to determine. In the recent cohort study conducted at Mayo Clinic, RS 
was diagnosed in 37/1,641 patients, and in approximately half of the patients the diagnosis 
occurred prior to any specific CLL treatment. Among the treated patients, the exposure to 
a combination of purine analogues and alkylating agents was associated with a higher risk 
of RS as compared to both agents administered alone (OR 3.26) [11]. This is in contrast 
with the results of two other studies, which showed no difference in RS incidence in 
patients treated with purine analogues, alkylating agents, or a combination of the two 
[19,20]. 
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With the current availability of novel non-chemoterapic drugs, such as Bruton tyrosine 
kinase (BTK) inhibitors, phosphatidylinositol-3-kinases (PI3K) inhibitor, and BCL-2 
antagonists for the treatment of CLL, a new clinical landscape emerges. Two independent 
studies showed an incidence of RS of 5-6% in patients undergoing ibrutinib therapy, and 
the majority of these patients transformed within the first 12 months of therapy [21,22]. 
More data are needed to exclude that the transformation to RS was driven by the 
treatment itself (i.e. contributing to the clonal evolution), even if the short time between the 
treatment initiation and the development of RS could suggests the presence of an 
unrecognized RS at the initiation of ibrutinib. Furthermore, future studies evaluating the 
development of RS in patients treated with other targeted treatments will be helpful to 
answer this open question. 
 
Biological and molecular risk factors 
Substantial efforts have been directed to the identification of biological characteristics of 
the CLL cells that could predict the transformation to RS. Several characteristics of the 
CLL cells with a recognized prognostic impact have been shown to also influence the 
transformation to an aggressive disease. Patients carrying unmutated IGHV or high-risk 
genetic abnormalities (i.e. del11q and del17p) detected by fluorescence in situ 
hybridization, as well as patients with high expression of CD38, ZAP70 and CD49d in CLL 
cells have a higher risk of developing RS [11,13].  
The usage of stereotyped B cell receptor (BCR) characterizes approximately one third of 
CLL cases, and it was found to be associated with a higher risk of transformation to RS 
(14% vs 4% 5-year risk) [10]. These data were later confirmed in an independent cohort of 
patients (5% vs 1%) [11]. Moreover, the association between the preferential use of IGHV 
4-39 and the development of RS was initially described, but later not confirmed, possibly 
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due to the association of this molecular characteristic with other unfavourable genetic 
features such as NOTCH1 mutations and trisomy 12 [10,11,23].  
One of the most important molecular features recently reported is NOTCH1 mutation 
which characterizes patients with CLL at increased risk of transformation to RS [24,25]. 
Short telomeres, an indicator of genetic instability, have been shown to serve not only as a 
negative prognostic biomarker in CLL, but also as a predictor of RS transformation [26]. 
However, not all negative prognosticators in CLL maintain a role in the development of RS. 
For example, SF3B1 mutations have no impact on the risk of transformation to an 
aggressive disease as shown in a cohort of 605 patients with CLL [25]. This is an 
important finding, highlighting how the biologic and molecular pathways leading to RS 
differ, at least in part, from the ones involved in CLL aggressiveness. 
In the quest for other possible risk factors for the development of RS, single nucleotide 
polymorphisms (SNPs) have also been studied. In a group of 248 patients with CLL, a 
SNP in the CD38 gene (rs6449182) was shown to have a higher frequency in patients 
carrying other markers of unfavorable prognosis and in patients who developed RS [27]. In 
another cohort of 331 patients with CLL, a significant association with the risk of 
transformation to RS was found for a SNP on the LRP4 gene (rs2306029) that codes for a 
protein with a role in the Wnt/β-catenin signaling pathway, which is known to be 
deregulated in CLL [28]. 
Of note, the majority of the reported data derive from retrospective cohort analysis, and 
prospective studies are therefore needed to validate these observations. 
 
Diagnostic approach 
The suspicion for RS is generally clinical. The clinical presentation is similar for patients 
with classical RS and HVRS. Patients typically present with systemic symptoms, such as 
persistent fever without a detectable infectious source or weight loss, high levels of lactate 
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dehydrogenase (LDH), hypercalcemia, and rapidly progressive lymphoadenopathies. 
Since these signs and symptoms are not specific for RS, but they may also accompany a 
progression of CLL without transformation, a histological diagnosis is mandatory. RS does 
not usually equally involve all lymph nodes, therefore a PET scan is recommended not 
only to evaluate the proliferative activity of the disease, but also to better direct the 
histological sampling to the most suitable area. 
The first study exploring the diagnostic performance of PET scan in detecting RS was 
published in 2006, and showed that using as a SUVmax cut-off of 5 the sensitivity and 
negative predictive value were high (91% and 97%, respectively) [29]. Similar percentages 
(sensitivity 88%, negative predictive value 92-94%) were confirmed in two later studies 
analyzing 95 and 17 patients with RS, respectively [30,31]. However, it has been recently 
shown in a cohort of 24 patients with RS that a SUVmax threshold of >10 may be more 
accurate in correctly classifying the patients [32]. PET scan does not discriminate between 
RS, non-hematological malignancies, infections, and CLL with high FDG avidity, and the 
low positive predictive value of this test (38-53%) strongly advocates for a histological 
confirmation in all cases of SUVmax ≥5 [30,31]. A lymph node biopsy, directed to a site of 
highly FDG-avid disease, should be preferred because fine needle aspirates are usually 
not sufficient to obtain a definitive diagnosis and have been shown to be inadequate in 
more than half of the RS cases [30]. From an histopathological point of view, the 
differential diagnosis includes “accelerated CLL” (characterized by expanded proliferation 
centers without histologically proven DLBCL) [33], prolymphocytic transformation [34], 
composite lymphoma (concomitant finding of two different lymphoproliferative diseases at 
the same time in the same tissue) [35], as well as unrelated causes such as infections and 
other neoplastic diseases. 
Interestingly, it has recently been shown that patients with CLL whose histology is showing 
different grades of aggressiveness, but have similar SUVmax, have comparable clinical 
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outcomes. In this study, patients with CLL, high SUV and histological features of 
intermediate aggressiveness (increased large cells, large confluent proliferation centers, or 
high proliferation rate) showed a clinical behavior similar to that of patients with RS, and a 
survival intermediate between patients with indolent CLL and RS [30].  
Although rare, extranodal localization of RS has been reported and may in some cases be 
detected by the PET scan. In particular, there are anecdotal cases of ocular, central 
nervous system (CNS), gastrointestinal system, skin, testis, lung, and kidney localization 
(reviewed in [36]). Beside tissue biopsies, a bone marrow biopsy and aspirate should also 
be performed in all patients to complete the staging. 
Lastly, it should also be strongly emphasized that there is currently no clinical value of the 
PET scan for routine evaluation of CLL in the absence of a clinical suspicion of 
transformation [37]. 
 
Prognosis 
As previously discussed, one of the main determinant of survival in patients with RS is the 
clonal relationship between the original CLL and the transformed disease. In clonally 
unrelated cases the median survival is comparable with de novo DLBCL and is 
significantly longer compared to patients with clonally related RS [5]. In clonally related 
RS, median survival varies between series, mostly between 8-24 months. In a series of 50 
clonally related patients with RS an overall survival (OS) of 14.2 months (95% CI 7.7-20.6 
months) was reported [5]. Another group reported a median survival of 8 months (95% CI 
6-10 months) in a cohort of 148 patients with biopsy or FNA-proven RS [9]. In a cohort of 
37 patients studied at Mayo Clinic, the median OS after development of RS was 2.1 years 
[11], and Mauro et al. reported an OS probability at 40 months of 13% for patients with a 
histologically-confirmed RS [31]. The OS in a retrospective series of 86 cases of HVRS 
was 1.7 years from RS diagnosis [12]. 
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Several models based on clinical and laboratory features have been developed to help 
determining the prognosis of patients with RS, considering that the assays to analyze the 
clonal relationship between CLL and RS are cumbersome and not available in all centers. 
A score which was able to predict the risk of death in patients with RS, taking into account 
performance status, LDH level, platelet count, and number of prior lines of therapy was 
developed at The University of Texas MD Anderson Cancer Center [9]. The validity of this 
score was later proven by an independent group on a different cohort of patients [11]. 
Another algorithm based on TP53 disruption, response to RS treatment, and performance 
status has been shown to predict RS prognosis, with survival durations ranging from less 
than one year for high risk patients to a 5-year survival of 70% for low risk patients [5]. 
Moreover, it has also been shown that a higher SUVmax at PET scan correlates with 
inferior survival in patients with RS, and that PET response – being an indicator of 
chemosensitivity – correlates with prognosis. In fact, in chemoresistant patients the 
median OS is significantly shorter compared to chemosensitive patients (15.3 months vs 
not reached at a median follow-up of 35.9 months) [30]. 
 
Therapeutic approach 
Whereas it is overall accepted that clonally unrelated transformation to DLBCL should be 
managed and treated as a de novo DLBCL, more uncertainty exists for clonally related 
RS. Due to the low incidence of RS, all data on treatment response and tolerability derive 
from single-arm phase II studies or retrospective analysis, and there are no available 
evidences from randomized trials. The most relevant results from clinical trials exploring 
different therapeutic approaches in RS are shown in Table 1. 
Historically, anthracycline-based regimens (most commonly cyclophosphamide, 
doxorubicin, vincristine, and prednisone, CHOP) possibly in association with rituximab (R-
CHOP), derived from the standard treatment of B cell lymphomas, have been used to treat 
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patients with RS [38,39]. However, a systematic evaluation of the efficacy of R-CHOP 
regimen in patients with RS was recently published and outlined its modest activity. 
Langerbeins and colleagues reported the results on 15 patients with RS and showed an 
overall response rate (ORR) of 67%, a progression free survival (PFS) of 10 months and 
an OS of 21 months. Moreover, a high incidence of severe infections (28%), hematologic 
toxicities (92%), and a treatment related mortality of 5% were reported [40]. The addition of 
rituximab to chemotherapy is confirmed to improve the OS of patients with RS in a 
retrospective cohort of 81 patients (2-year OS 42% vs 19%, p= 0.001) [41]. A phase II 
study evaluating efficacy and tolerability of CHOP in combination with ofatumumab as 
induction and maintenance for patients with newly diagnosed RS is currently ongoing, but 
results have not been presented yet [42]. 
With the aim of improving the treatment efficacy, other anthracycline-based regimens have 
been evaluated in clinical trials. Twenty-nine patients were treated at The University of 
Texas MD Anderson Cancer Center with fractionated cyclophosphamide, vincristine, 
liposomal daunorubicin and dexamethasone, obtaining an ORR of 41%, with high rate of 
complete response (CR) (38%), but an OS of only 10 months [43]. A further development 
of this treatment schema, which alternated this regimen with  high-dose methotrexate and 
cytarabine every other cycle and incorporated rituximab and granulocyte-macrophage-
colony stimulating factor (GM-CSF), was used to treat 30 patients resulting in an ORR of 
41% and an OS of 8.5 months. The toxicity of this treatment was high with 18% of patients 
dying during the first cycle of therapy [44]. 
The combination of cisplatin, fludarabine, cyclophosphamide, and cytarabine was also 
evaluated in 15 patients with RS showing dismal results (5% ORR, 20% treatment-related 
mortality in the first month) [45]. The rationale for developing this regimen is based on 
preclinical data demonstrating synergistic cytotoxic activity of cisplatin and the nucleoside 
analogue fludarabine [46,47], and showing that the administration of fludarabine before 
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cytarabine increases the cellular concentration of the active metabolite, cytarabine 
triphosphate [48]. 
Another platinum-based regimen for patients with RS based on the above described 
pharmacological rationale was developed at our center combining oxaliplatin, fludarabine, 
cytarabine and rituximab (OFAR). The activity of this treatment combination was explored 
in two trials: a total of 55 patients were treated with different dosing schedules obtaining 
ORR of 43-50% and a median survival of 6-8 months. The most significant toxicities of this 
regimen were hematologic and infectious, with >80% rate of grade 3-4 neutropenia and 
12-15% rate of grade 3-4 neutropenic fever [49,50]. Similar results were shown in a 
retrospective analysis evaluating the efficacy of platinum and cytarabine-based regimens 
in 28 patients with RS, performed by Durot and colleagues, which showed an ORR of 43% 
with 25% CR, and a median OS of 8.3 months [51]. 
Based on its efficacy in treating patients with other B cell lymphomas, 90Y ibritumomab 
tiuxetan was also tested in 7 patients with RS, showing no responses and a median PFS 
of only 41 days [52]. 
Regarding the rare HVRS form, a retrospective systematic review of patients with CLL who 
developed HVRS between 1975 and 2011 identified 86 cases and confirmed that the 
combination of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) is the most 
commonly offered treatment strategy [12]. 
In the last few years, the therapeutic landscape for CLL and other B cell lymphomas has 
dramatically changed, with the introduction of small molecule inhibitors. Among these 
agents, ibrutinib has shown a remarkable efficacy in patients with CLL [53]. Ibrutinib has 
also demonstrated single-agent activity in patients with relapsed/refractory de novo 
DLBCL, and interestingly, the produced ORR was higher in patients with the more 
aggressive ABC DLBCL compared to GCB DLBCL (n=80, 37% vs 5%, p=0.0106) [54]. In 
de novo DLBCL, the combination of ibrutinib with R-CHOP has also been explored and all 
14 
 
18 patients who received the recommended phase II dose of ibrutinib (560 mg/die) 
obtained a response [55]. Based on these findings, the use of ibrutinib (with or without 
rituximab) in patients with RS has been proposed and anecdotic data were published [56-
58]. In most cases patients were heavily pretreated and some responses were observed, 
but results are inconsistent and further studies to explore the efficacy of BTK inhibitors in 
clinical trials, also in combination with other drugs, are needed. Moreover, the efficacy of 
other novel drugs such as BCL-2 antagonists, PI3K inhibitors and NOTCH1 inhibitors in 
patients with RS is being evaluated in recently designed studies. 
Stem cell transplant (SCT) plays a role in the treatment of patients with RS. Only a 
minority of patients (<15%) can undergo the procedure due to disease refractoriness and 
poor performance status. In the clinical database at The Univeristy of Texas MD Anderson 
Cancer Center, 148 patients with proven RS were identified between 1975 and 2005. 
Fourteen% of these patients underwent SCT (17 alloSCT and 3 autoSCT), and they had a 
better long-term outcome compared to patients who did not. Moreover, the estimated 
cumulative 3-year survival probability for patients who received the SCT while in CR or PR 
was 75%, compared with 21% for patients who did not achieve a response prior to SCT 
[9]. Patients with RS seen at Mayo Clinic between 1995 and 2013 were also studied 
(n=120). Only 11% received a SCT (8% autoSCT, 2% alloSCT and 1% autoSCT followed 
by alloSCT) and the median OS of these patients was superior compared to those who did 
not undergo SCT (5.2 years vs 0.7 years, p=0.005) [59]. In a multicenter restrospective 
analysis, 59 patients with RS were analyzed: 34 patients received autoSCT and 25 
received alloSCT, with 36% being refractory to chemotherapy at SCT. Reduced-intensity 
conditioning (RIC) was used in 72% of cases, and was found to be associated with longer 
relapse-free survival (RFS) after alloSCT in multivariate analysis. Three-year estimates of 
the probabilities of OS and RFS were 36% and 27% for alloSCT, and 59% and 45% for 
autoSCT [60]. In this latter study, also the disease status at the time of SCT was 
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associated with survival, highlighting the potential utility of this procedure in a selected 
group of patients with a good performance status and a disease that is sensitive to 
chemotherapy. 
 
Conclusions 
RS remains a rare clinical occurrence. The low incidence explains the paucity of definitive 
data on the pathogenesis and prognosis of this disease, and also the difficulty in 
conducting clinical trials to explore new treatments. 
The increasing understanding of the molecular mechanisms underlying RS transformation 
and of the relevant risk factors may help the clinicians to identify high-risk patients with 
CLL, who might need to be followed more strictly as compared to patients with indolent 
disease. 
RS is still an unmet clinical need and current data on treatment approaches mainly derives 
from small non-randomized trials. The available therapeutic strategies are not satisfactory: 
besides the low efficacy, they carry a high mortality and adverse event rate, possibly due 
also to the fact that patients are frequently heavily pretreated and with a poor performance 
status. The availability of new drugs with novel mechanisms of action (i.e. BCR inhibitors 
and BCL-2 antagonists), which are characterized by a better tolerability compared to 
standard intensive chemotherapy, offers promising new tools for this aggressive disease. 
Moreover, the growing understanding of the molecular basis of RS will hopefully help to 
identify novel therapeutic targets. 
 
  
16 
 
References 
1. Richter MN (1928) Generalized Reticular Cell Sarcoma of Lymph Nodes Associated 
with Lymphatic Leukemia. The American journal of pathology 4 (4):285-292.287 
2. Lortholary P, Boiron M, Ripault P, Levy JP, Manus A, Bernard J (1964) Chronic 
lymphoid leukemia secondarily associated with a malignant reticulopathy: Richter's 
syndrome. Nouvelle revue francaise d'hematologie 4:621-644 
3. Swerdlow SH, Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., 
Vardiman, J.W (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid 
Tissues, Fourth Edition. In:    
.  
4. Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, Braziel RM, 
Geng H, Iqbal J, Lenz G, Vose JM, Hans CP, Fu K, Smith LM, Li M, Liu Z, Gascoyne RD, 
Rosenwald A, Ott G, Rimsza LM, Campo E, Jaffe ES, Jaye DL, Staudt LM, Chan WC 
(2009) A new immunostain algorithm classifies diffuse large B-cell lymphoma into 
molecular subtypes with high accuracy. Clinical cancer research : an official journal of the 
American Association for Cancer Research 15 (17):5494-5502. doi:10.1158/1078-
0432.ccr-09-0113 
5. Rossi D, Spina V, Deambrogi C, Rasi S, Laurenti L, Stamatopoulos K, Arcaini L, Lucioni 
M, Rocque GB, Xu-Monette ZY, Visco C, Chang J, Chigrinova E, Forconi F, Marasca R, 
Besson C, Papadaki T, Paulli M, Larocca LM, Pileri SA, Gattei V, Bertoni F, Foa R, Young 
KH, Gaidano G (2011) The genetics of Richter syndrome reveals disease heterogeneity 
and predicts survival after transformation. Blood 117 (12):3391-3401. doi:10.1182/blood-
2010-09-302174 
6. Mao Z, Quintanilla-Martinez L, Raffeld M, Richter M, Krugmann J, Burek C, Hartmann 
E, Rudiger T, Jaffe ES, Muller-Hermelink HK, Ott G, Fend F, Rosenwald A (2007) IgVH 
mutational status and clonality analysis of Richter's transformation: diffuse large B-cell 
lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia 
(B-CLL) represent 2 different pathways of disease evolution. The American journal of 
surgical pathology 31 (10):1605-1614. doi:10.1097/PAS.0b013e31804bdaf8 
7. Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner 
S, Bueso-Ramos CE, Keating MJ (2006) Hodgkin transformation of chronic lymphocytic 
leukemia: the M. D. Anderson Cancer Center experience. Cancer 107 (6):1294-1302. 
doi:10.1002/cncr.22121 
8. Mauro FR, Foa R, Giannarelli D, Cordone I, Crescenzi S, Pescarmona E, Sala R, 
Cerretti R, Mandelli F (1999) Clinical characteristics and outcome of young chronic 
lymphocytic leukemia patients: a single institution study of 204 cases. Blood 94 (2):448-
454 
9. Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, Wen S, Do 
KA, Smith SC, Lerner S, Freireich EJ, Keating MJ (2006) Clinical outcomes and prognostic 
17 
 
factors in patients with Richter's syndrome treated with chemotherapy or 
chemoimmunotherapy with or without stem-cell transplantation. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology 24 (15):2343-2351. 
doi:10.1200/jco.2005.05.0187 
10. Rossi D, Spina V, Cerri M, Rasi S, Deambrogi C, De Paoli L, Laurenti L, Maffei R, 
Forconi F, Bertoni F, Zucca E, Agostinelli C, Cabras A, Lucioni M, Martini M, Magni M, 
Deaglio S, Ladetto M, Nomdedeu JF, Besson C, Ramponi A, Canzonieri V, Paulli M, 
Marasca R, Larocca LM, Carbone A, Pileri SA, Gattei V, Gaidano G (2009) Stereotyped B-
cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation 
to Richter syndrome. Clinical cancer research : an official journal of the American 
Association for Cancer Research 15 (13):4415-4422. doi:10.1158/1078-0432.ccr-08-3266 
11. Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, Leis JF, Schwager 
SM, Hanson CA, Macon WR, Kay NE, Slager SL, Shanafelt TD (2013) Diffuse large B-cell 
lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a 
cohort study of newly diagnosed patients. British journal of haematology 162 (6):774-782. 
doi:10.1111/bjh.12458 
12. Bockorny B, Codreanu I, Dasanu CA (2012) Hodgkin lymphoma as Richter 
transformation in chronic lymphocytic leukaemia: a retrospective analysis of world 
literature. British journal of haematology 156 (1):50-66. doi:10.1111/j.1365-
2141.2011.08907.x 
13. Rossi D, Cerri M, Capello D, Deambrogi C, Rossi FM, Zucchetto A, De Paoli L, Cresta 
S, Rasi S, Spina V, Franceschetti S, Lunghi M, Vendramin C, Bomben R, Ramponi A, 
Monga G, Conconi A, Magnani C, Gattei V, Gaidano G (2008) Biological and clinical risk 
factors of chronic lymphocytic leukaemia transformation to Richter syndrome. British 
journal of haematology 142 (2):202-215. doi:10.1111/j.1365-2141.2008.07166.x 
14. Fabbri G, Khiabanian H, Holmes AB, Wang J, Messina M, Mullighan CG, Pasqualucci 
L, Rabadan R, Dalla-Favera R (2013) Genetic lesions associated with chronic lymphocytic 
leukemia transformation to Richter syndrome. The Journal of experimental medicine 210 
(11):2273-2288. doi:10.1084/jem.20131448 
15. Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PM, Strefford JC, Oscier D, 
Stamatopoulos K, Papadaki T, Berger F, Young KH, Murray F, Rosenquist R, Greiner TC, 
Chan WC, Orlandi EM, Lucioni M, Marasca R, Inghirami G, Ladetto M, Forconi F, Cogliatti 
S, Votavova H, Swerdlow SH, Stilgenbauer S, Piris MA, Matolcsy A, Spagnolo D, Nikitin E, 
Zamo A, Gattei V, Bhagat G, Ott G, Zucca E, Gaidano G, Bertoni F (2013) Two main 
genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter 
syndrome. Blood 122 (15):2673-2682. doi:10.1182/blood-2013-03-489518 
16. Rinaldi A, Mensah AA, Kwee I, Forconi F, Orlandi EM, Lucioni M, Gattei V, Marasca R, 
Berger F, Cogliatti S, Cavalli F, Zucca E, Gaidano G, Rossi D, Bertoni F (2013) Promoter 
methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle 
regulation and differ from de novo diffuse large B-cell lymphoma. British journal of 
haematology 163 (2):194-204. doi:10.1111/bjh.12515 
18 
 
17. Rossi D, Khiabanian H, Spina V, Ciardullo C, Bruscaggin A, Fama R, Rasi S, Monti S, 
Deambrogi C, De Paoli L, Wang J, Gattei V, Guarini A, Foa R, Rabadan R, Gaidano G 
(2014) Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. 
Blood 123 (14):2139-2147. doi:10.1182/blood-2013-11-539726 
18. Dolcetti R, Carbone A (2010) Epstein-Barr virus infection and chronic lymphocytic 
leukemia: a possible progression factor? Infectious agents and cancer 5:22. 
doi:10.1186/1750-9378-5-22 
19. Solh M, Rai KR, Peterson BL, Kolitz JE, Appelbaum FR, Tallman MS, Belch A, Larson 
RA, Morrison VA (2013) The impact of initial fludarabine therapy on transformation to 
Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic 
leukemia: analysis of an intergroup trial (CALGB 9011). Leuk Lymphoma 54 (2):252-254. 
doi:10.3109/10428194.2012.710327 
20. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, Pettitt AR, 
Hamblin T, Milligan DW, Child JA, Hamilton MS, Dearden CE, Smith AG, Bosanquet AG, 
Davis Z, Brito-Babapulle V, Else M, Wade R, Hillmen P (2007) Assessment of fludarabine 
plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 
Trial): a randomised controlled trial. Lancet 370 (9583):230-239. doi:10.1016/s0140-
6736(07)61125-8 
21. Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, George B, James D, 
Kantarjian H, Burger J, O'Brien S (2015) Outcomes of patients with chronic lymphocytic 
leukemia after discontinuing ibrutinib. Blood 125 (13):2062-2067. doi:10.1182/blood-2014-
09-603670 
22. Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, 
Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, 
Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA (2015) Etiology of 
Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic 
Leukemia. JAMA oncology 1 (1):80-87. doi:10.1001/jamaoncol.2014.218 
23. Rossi D, Spina V, Bomben R, Rasi S, Dal-Bo M, Bruscaggin A, Rossi FM, Monti S, 
Degan M, Ciardullo C, Serra R, Zucchetto A, Nomdedeu J, Bulian P, Grossi A, Zaja F, 
Pozzato G, Laurenti L, Efremov DG, Di-Raimondo F, Marasca R, Forconi F, Del Poeta G, 
Gaidano G, Gattei V (2013) Association between molecular lesions and specific B-cell 
receptor subsets in chronic lymphocytic leukemia. Blood 121 (24):4902-4905. 
doi:10.1182/blood-2013-02-486209 
24. Villamor N, Conde L, Martinez-Trillos A, Cazorla M, Navarro A, Bea S, Lopez C, 
Colomer D, Pinyol M, Aymerich M, Rozman M, Abrisqueta P, Baumann T, Delgado J, Gine 
E, Gonzalez-Diaz M, Hernandez JM, Colado E, Payer AR, Rayon C, Navarro B, Jose 
Terol M, Bosch F, Quesada V, Puente XS, Lopez-Otin C, Jares P, Pereira A, Campo E, 
Lopez-Guillermo A (2013) NOTCH1 mutations identify a genetic subgroup of chronic 
lymphocytic leukemia patients with high risk of transformation and poor outcome. 
Leukemia 27 (5):1100-1106. doi:10.1038/leu.2012.357 
19 
 
25. Rossi D, Rasi S, Spina V, Fangazio M, Monti S, Greco M, Ciardullo C, Fama R, Cresta 
S, Bruscaggin A, Laurenti L, Martini M, Musto P, Forconi F, Marasca R, Larocca LM, Foa 
R, Gaidano G (2012) Different impact of NOTCH1 and SF3B1 mutations on the risk of 
chronic lymphocytic leukemia transformation to Richter syndrome. British journal of 
haematology 158 (3):426-429. doi:10.1111/j.1365-2141.2012.09155.x 
26. Rossi D, Lobetti Bodoni C, Genuardi E, Monitillo L, Drandi D, Cerri M, Deambrogi C, 
Ricca I, Rocci A, Ferrero S, Bernocco E, Capello D, De Paoli L, Bergui L, Boi M, Omede P, 
Massaia M, Tarella C, Passera R, Boccadoro M, Gaidano G, Ladetto M (2009) Telomere 
length is an independent predictor of survival, treatment requirement and Richter's 
syndrome transformation in chronic lymphocytic leukemia. Leukemia 23 (6):1062-1072. 
doi:10.1038/leu.2008.399 
27. Aydin S, Rossi D, Bergui L, D'Arena G, Ferrero E, Bonello L, Omede P, Novero D, 
Morabito F, Carbone A, Gaidano G, Malavasi F, Deaglio S (2008) CD38 gene 
polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter 
syndrome? Blood 111 (12):5646-5653. doi:10.1182/blood-2008-01-129726 
28. Rasi S, Spina V, Bruscaggin A, Vaisitti T, Tripodo C, Forconi F, De Paoli L, Fangazio 
M, Sozzi E, Cencini E, Laurenti L, Marasca R, Visco C, Xu-Monette ZY, Gattei V, Young 
KH, Malavasi F, Deaglio S, Gaidano G, Rossi D (2011) A variant of the LRP4 gene affects 
the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. British 
journal of haematology 152 (3):284-294. doi:10.1111/j.1365-2141.2010.08482.x 
29. Bruzzi JF, Macapinlac H, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, 
Munden RF (2006) Detection of Richter's transformation of chronic lymphocytic leukemia 
by PET/CT. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 
47 (8):1267-1273 
30. Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, Sargent RL, Trinh L, Wang 
X, Smith SC, Jain N, Estrov Z, O'Brien S, Wierda WG, Lerner S, Ferrajoli A (2014) 
Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with 
chronic lymphoid leukemia. Blood 123 (18):2783-2790. doi:10.1182/blood-2013-11-536169 
31. Mauro FR, Chauvie S, Paoloni F, Biggi A, Cimino G, Rago A, Gentile M, Morabito F, 
Coscia M, Bello M, Sacchetti GM, Rossi D, Laurenti L, Autore F, Campanelli M, Trastulli F, 
Nicolai E, Riminucci M, Gaidano G, Guarini A, Gallamini A, Foa R (2015) Diagnostic and 
prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive 
disease. Leukemia 29 (6):1360-1365. doi:10.1038/leu.2015.21 
32. Michallet AS, Sesques P, Rabe KG, Itti E, Tordot J, Tychyj-Pinel C, Baseggio L, Subtil 
F, Salles G, Dupuis JM, Conte MJ (2015) An 18F-FDG-PET maximum standardized 
uptake value >10 represents a novel valid marker for discerning Richter's Syndrome. Leuk 
Lymphoma:1-10. doi:10.3109/10428194.2015.1099643 
33. Gine E, Martinez A, Villamor N, Lopez-Guillermo A, Camos M, Martinez D, Esteve J, 
Calvo X, Muntanola A, Abrisqueta P, Rozman M, Rozman C, Bosch F, Campo E, 
Montserrat E (2010) Expanded and highly active proliferation centers identify a histological 
20 
 
subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with 
aggressive clinical behavior. Haematologica 95 (9):1526-1533. 
doi:10.3324/haematol.2010.022277 
34. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen 
P, Keating MJ, Montserrat E, Rai KR, Kipps TJ (2008) Guidelines for the diagnosis and 
treatment of chronic lymphocytic leukemia: a report from the International Workshop on 
Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 
1996 guidelines. Blood 111 (12):5446-5456. doi:10.1182/blood-2007-06-093906 
35. Kuppers R, Duhrsen U, Hansmann ML (2014) Pathogenesis, diagnosis, and treatment 
of composite lymphomas. The Lancet Oncology 15 (10):e435-446. doi:10.1016/s1470-
2045(14)70153-6 
36. Omoti CE, Omoti AE (2008) Richter syndrome: a review of clinical, ocular, neurological 
and other manifestations. British journal of haematology 142 (5):709-716. 
doi:10.1111/j.1365-2141.2008.07248.x 
37. Conte MJ, Bowen DA, Wiseman GA, Rabe KG, Slager SL, Schwager SM, Call TG, 
Viswanatha DS, Zent CS (2014) Use of positron emission tomography-computed 
tomography in the management of patients with chronic lymphocytic leukemia/small 
lymphocytic lymphoma. Leuk Lymphoma 55 (9):2079-2084. 
doi:10.3109/10428194.2013.869801 
38. Robertson LE, Pugh W, O'Brien S, Kantarjian H, Hirsch-Ginsberg C, Cork A, 
McLaughlin P, Cabanillas F, Keating MJ (1993) Richter's syndrome: a report on 39 
patients. Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology 11 (10):1985-1989 
39. Harousseau JL, Flandrin G, Tricot G, Brouet JC, Seligmann M, Bernard J (1981) 
Malignant lymphoma supervening in chronic lymphocytic leukemia and related disorders. 
Richter's syndrome: a study of 25 cases. Cancer 48 (6):1302-1308 
40. Langerbeins P, Busch R, Anheier N, Durig J, Bergmann M, Goebeler ME, Hurtz HJ, 
Stauch MB, Stilgenbauer S, Dohner H, Fink AM, Cramer P, Fischer K, Wendtner CM, 
Hallek M, Eichhorst B (2014) Poor efficacy and tolerability of R-CHOP in 
relapsed/refractory chronic lymphocytic leukemia and Richter transformation. American 
journal of hematology 89 (12):E239-243. doi:10.1002/ajh.23841 
41. Tadmor T, Shvidel L, Bairey O, Goldschmidt N, Ruchlemer R, Fineman R, Rahimi-
Levene N, Herishanu Y, Yuklea M, Arad A, Aviv A, Polliack A (2014) Richter's 
transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical 
data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL 
Study Group. American journal of hematology 89 (11):E218-222. doi:10.1002/ajh.23826 
42. Eyre TA, Clifford R, Roberts C, Boyle L, Francis A, Schuh A, Dutton SJ (2015) Single 
arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and 
21 
 
maintenance for patients with newly diagnosed Richter's syndrome. BMC cancer 15:52. 
doi:10.1186/s12885-015-1048-9 
43. Dabaja BS, O'Brien SM, Kantarjian HM, Cortes JE, Thomas DA, Albitar M, Schlette 
ES, Faderl S, Sarris A, Keating MJ, Giles FJ (2001) Fractionated cyclophosphamide, 
vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) 
regimen in Richter's syndrome. Leuk Lymphoma 42 (3):329-337. 
doi:10.3109/10428190109064589 
44. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, 
Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles 
FJ (2003) Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and 
dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor 
(GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in 
patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. 
Cancer 97 (7):1711-1720. doi:10.1002/cncr.11238 
45. Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, Keating 
MJ, Giles FJ (2002) Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, 
cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory 
lymphoproliferative disorders. Leuk Lymphoma 43 (4):767-772. 
doi:10.1080/10428190290016872 
46. Yang LY, Li L, Keating MJ, Plunkett W (1995) Arabinosyl-2-fluoroadenine augments 
cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Molecular pharmacology 
47 (5):1072-1079 
47. Li L, Liu X, Glassman AB, Keating MJ, Stros M, Plunkett W, Yang LY (1997) 
Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA 
adducts in vitro. Cancer research 57 (8):1487-1494 
48. Gandhi V, Kemena A, Keating MJ, Plunkett W (1992) Fludarabine infusion potentiates 
arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic 
leukemia. Cancer research 52 (4):897-903 
49. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, 
Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner 
S, Kantarjian HM, Keating MJ (2008) Phase I-II study of oxaliplatin, fludarabine, 
cytarabine, and rituximab combination therapy in patients with Richter's syndrome or 
fludarabine-refractory chronic lymphocytic leukemia. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology 26 (2):196-203. 
doi:10.1200/jco.2007.11.8513 
50. Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, 
Badoux X, Kantarjian H, Keating MJ (2013) Phase I-II clinical trial of oxaliplatin, 
fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic 
lymphocytic leukemia or Richter syndrome. Clinical lymphoma, myeloma & leukemia 13 
(5):568-574. doi:10.1016/j.clml.2013.03.012 
22 
 
51. Durot E, Michallet AS, Lepretre S, Le QH, Leblond V, Delmer A (2015) Platinum and 
high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic 
lymphocytic leukemia and Richter's syndrome: results of a French retrospective 
multicenter study. European journal of haematology 95 (2):160-167. doi:10.1111/ejh.12474 
52. Tsimberidou AM, Murray JL, O'Brien S, Wierda WG, Keating MJ (2004) Yttrium-90 
ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. Cancer 100 (10):2195-
2200. doi:10.1002/cncr.20252 
53. Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, 
Jones JA, Zhao W, Heerema NA, Johnson AJ, Shaw Y, Bilotti E, Zhou C, James DF, 
O'Brien S (2015) Three-year follow-up of treatment-naive and previously treated patients 
with CLL and SLL receiving single-agent ibrutinib. Blood 125 (16):2497-2506. 
doi:10.1182/blood-2014-10-606038 
54. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams 
PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov 
A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC (2015) 
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.  21 
(8):922-926. doi:10.1038/nm.3884 
55. Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, 
Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, 
Smit JW, Fourneau N, Oki Y (2014) Combination of ibrutinib with rituximab, 
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive 
patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b 
study. The Lancet Oncology 15 (9):1019-1026. doi:10.1016/s1470-2045(14)70311-0 
56. Giri S, Hahn A, Yaghmour G, Martin MG (2015) Ibrutinib has some activity in Richter's 
syndrome. Blood cancer journal 5:e277. doi:10.1038/bcj.2014.98 
57. Lamar Z, Kennedy L, Kennedy B, Lynch M, Goad A, Hurd D, McIver Z (2015) Ibrutinib 
and rituximab induced rapid response in refractory Richter syndrome. Clinical case reports 
3 (7):615-617. doi:10.1002/ccr3.269 
58. Tsang M, Shanafelt TD, Call TG, Ding W, Chanan-Khan A, Leis JF, Nowakowski GS, 
Bowen D, Conte M, Schwager SM, Slager SL, Kay NE, Hanson CA, Parikh SA (2015) The 
efficacy of ibrutinib in the treatment of Richter syndrome. Blood 125 (10):1676-1678. 
doi:10.1182/blood-2014-12-610782 
59. Sharma RG, Call TG, Habermann TM, Ding W, Leis JF, Schwager S, Hanson CA, 
Macon WR, Tschumper RC, Jelinek DF, Kay NE, Slager SL, Rabe KG, Shanafelt TD 
(2013) Outcomes Of Chronic Lymphocytic Leukemia Patients With Richter Syndrome. 
Blood 122 (21):4179-4179 
60. Cwynarski K, van Biezen A, de Wreede L, Stilgenbauer S, Bunjes D, Metzner B, Koza 
V, Mohty M, Remes K, Russell N, Nagler A, Scholten M, de Witte T, Sureda A, Dreger P 
(2012) Autologous and allogeneic stem-cell transplantation for transformed chronic 
23 
 
lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic 
lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma 
working party of the European Group for Blood and Marrow Transplantation. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology 30 
(18):2211-2217. doi:10.1200/jco.2011.37.4108 
 
 
24 
 
Table 1. Summary of key clinical trials for the treatment of RS 
Trial Regimen   Response Survival Toxicity 
Langerbeins et al.[40] 
Am J Hematol, 2014 
Phase II 
n=15 
R-CHOP 
(up to 8 cycles) 
 
- cyclophosphamide 750  mg/m2 D1 
- adriamycin 50 mg/m2 D1 
- vincristine 1,4 mg/m2 D1 
- prednisone 100 mg D1-D5 
- rituximab 375 mg/m2 D1 
ORR 67% 
CR 7% 
PR 60% 
 
PFS: 10 months 
OS: 21 months 
 
G3-4 anemia 75% 
G3-4 neutropenia 55% 
G3-4 thrombocytopenia 65% 
All grade infections 67% 
G3-4 infections 28% 
Dabaja et al. [43] 
Leuk Lymphoma, 2001 
Phase II 
n=29 
 
hyperCVXD 
(up to 6 cycles) 
- cyclophosphamide 300 mg/m2 twice daily D1-D3 
- vincristine 2 mg D4 and D11 
- daunoXome 40 mg/m2 D3-D5 
- dexamethasone 40 mg D1-4 and D11 
(+ G-CSF) 
ORR 41% 
CR 38% 
OS: 10 months G3-4 neutropenia 100% 
G3-4 infections 39% 
G3-4 thrombocytopenia 79% of the first 
cycles 
Pneumonia 15% of cycles 
Sepsis 8% of cycles 
Mortality rate 20% 
Tsimberidou et al. [44] 
Cancer, 2003 
Phase II 
n=30 
R-hyper-
CVXD/R-MTX-
Ara-C 
(alternating for 6 
cycles) 
 
CYCLES 1, 3, 5: 
- rituximab 375 mg/m2 D1 
- cyclophosphamide 300 mg/m2 twice daily D3-D5 in 
cycle 1, D1-3 cycle 3 and 5 
- vincristine 2 mg D6 and D13 in cycle 1, D4 and D11 
cycle 3 and 5 
- daunoXome 40 mg/m2 D5-D7 in cycle 1, D3-5 cycle 3 
and 5 
- dexamethasone 40 mg D3-D6 and D13-D16 in cycle 1, 
D1-4 and D11-D14 cycle 3 and 5 
CYCLES 2, 4, 6: 
- rituximab 375 mg/m2 D1 
- methotrexate 1 g/m2 D1 
- cytarabine 3 g/m2 twice daily D2-D3  
(+GM-CSF) 
ORR 41% 
CR 19% 
PR 22% 
OS: 8 months G4 neutropenia 100% 
G4 thrombocytopenia 40% of cycles 
G3-4 sepsis 39% of cycles  
Deaths during first cycle 18% 
Deaths during second cycle 4% 
 
Tsimberidou et al. [49] 
JCO, 2008 
Phase I/II 
n=20 
OFAR-1 
(up to 6 cycles) 
- oxaliplatin (17.5, 20, or 25 mg/m2 in phase I, 25 mg/m2 
in phase II) D1-D4 
- fludarabine 30 mg/m2 D2-D3 
- cytarabine 1 g/m2 D2-D3 
- rituximab 375mg/m2 cycle 1 D3, cycles 2-6 D1 
(+ pegfilgrastim) 
ORR 50% 
CR 20% 
 
6-month PFS: 54% 
6-month OS: 59% 
G4 neutropenia 84% 
G4 thrombocytopenia 94% 
G4 anemia 56% 
 
Tsimberidou et al. [50] 
Clin Lymp, Myel & Leuk, 2013 
Phase I/II 
n=35 
OFAR-2 
(up to 6 cycles) 
- oxaliplatin 30 mg/m2 D1-D4 
- fludarabine 30 mg/m2 D2-D3 or D2-D4 or D2-D5 
- cytarabine 0.5 g/m2 D2-D3 or D2-D4 or D2-D5 
- rituximab 375 mg/m2 cycle 1 D3, cycles 2-6 D1 
(+ pegfilgrastim) 
ORR 43% 
CR 9% 
 
OS: 6.6 months 
2-year OS: 19.7% 
G4 neutropenia 89% 
G4 thrombocytopenia 77% 
G4 anemia 50% 
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Figure 1. Decision points for diagnosis and management of RS 
 
 
